01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. Competitive Assessment of Top Drugs
08. Five Forces Analysis
09. Market Segmentation by Category
10. Geographical Segmentation
11. Buying Criteria
12. Rate of Incidence and Prevalence
12.1.1 US
12.1.2 UK
12.1.3 Asia
13. Pipeline Snapshot
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 AbbVie
21.1.1 Key Facts
21.1.2 Business Description
21.1.3 Product Segmentation
21.1.4 Revenue by Product Line
21.1.5 Revenue Comparison 2012 and 2013
21.1.6 Revenue by Geographical Segmentation
21.1.7 Business Strategy
21.1.8 Key Developments
21.1.9 SWOT Analysis
21.1.10 Strengths
21.1.11 Weaknesses
21.1.12 Opportunities
21.1.13 Threats
21.2 Amgen
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Product Segmentation by Revenue 2013
21.2.4 Geographical Segmentation by Revenue 2013
21.2.5 Business Strategy
21.2.6 Key Information
21.2.7 SWOT Analysis
21.2.8 Strengths
21.2.9 Weaknesses
21.2.10 Opportunities
21.2.11 Threats
21.3 Bristol-Myers Squibb
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Product Segmentation
21.3.4 Sales by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.3.8 Strengths
21.3.9 Weaknesses
21.3.10 Opportunities
21.3.11 Threats
21.4 F. Hoffmann La Roche
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.4.9 Strengths
21.4.10 Weaknesses
21.4.11 Opportunities
21.4.12 Threats
21.5 Janssen Pharmaceuticals
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation
21.5.4 Business Strategy
21.5.5 Key Developments
21.5.6 SWOT Analysis
21.5.7 Strengths
21.5.8 Weaknesses
21.5.9 Opportunities
21.5.10 Threats
21.6 Pfizer
21.6.1 Key Facts
21.6.2 Business Overview
21.6.3 Business Segmentation by Revenue 2013
21.6.4 Business Segmentation by Revenue 2012 and 2013
21.6.5 Sales by Geography
21.6.6 Business Strategy
21.6.7 Key Developments
21.6.8 SWOT Analysis
21.6.9 Strengths
21.6.10 Weaknesses
21.6.11 Opportunities
21.6.12 Threats
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Rheumatoid Arthritis Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Competitive Assessment of Top RA Drugs
Exhibit 4: Revenue Share of RA Drugs by Key Vendors 2013
Exhibit 5: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach
Exhibit 6: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach 2013
Exhibit 7: Global Rheumatoid Arthritis Drugs Market by Geographical Segmentation 2013
Exhibit 8: Global Rheumatoid Arthritis Drugs Market Share Analysis 2013
Exhibit 9: AbbVie Inc.: Product Segmentation
Exhibit 10: AbbVie Inc.: Revenue by Product Line 2013
Exhibit 11: AbbVie Inc.: Revenue Comparison by Product Line 2012 and 2013 (US$ billion)
Exhibit 12: AbbVie Inc.: Revenue by Geographical Segmentation 2013
Exhibit 13: Amgen: Product Segmentation by Revenue 2013
Exhibit 14: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 15: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 16: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 17: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 18: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 19: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 20: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 21: Janssen Pharmaceuticals Inc.: Product Segmentation 2013
Exhibit 22: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 23: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 24: Pfizer Inc.: Sales by Geography 2013
【掲載企業】
AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals Inc., Pfizer Inc. , AB Science SA, Astellas Pharma Inc., AstraZeneca plc, Biogen Idec Inc., Boehringer Ingelheim GmbH, Celgene Corp., Daiichi Sankyo Co. Ltd., Eli Lilly & Co., GE Healthcare Co., Genmab A/S, GSK plc, Incyte Corp., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novo Nordisk A/S, Rigel Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., UCB SA, Vertex Pharmaceuticals Inc.
【資料のキーワード】
関節リウマチ、治療、医薬品
【調査方法】
一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)